Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics. The company is the creator of three approved partnered antibodies, DARZALEX® (daratumumab) / subcutaneous DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the treatment of certain multiple myeloma indications, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and TEPEZZA™ (teprotumumab) for thyroid eye disease. Genmab also has a broad clinical and pre-clinical product pipeline and four proprietary next generation antibody technologies: the DuoBody®, HexaBody®, HexElect®, and the DuoHexaBody® platforms. Genmab is headquartered in Denmark with sites in the Netherlands, the U.S. and Japan.
Show Specials